WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP
Impact Factor 8.63
Volume 15, Issue 6, 25-46.
Review Article
ISSN 2277–7105

A REVIEW ON NANO TECHNOLOGY IN DRUG DELIVERY SYSTEM

Ms. Shradha Shriram Hambire[1]*, Mr. Shivraj Surayawanshi[2], Dr. Ganesh S. Tolsarwad[3]

[1]B. Pharm Student, Swami Vivekanand College of Pharmacy, Udgir, Latur, Maharashtra, India.

[2]Assistant Professor, Department of Pharmacy, Swami Vivekanand College of Pharmacy, Udgir, Maharashtra, India.

[3]M. Pharm. PhD.

Article Received on 16 Feb. 2026,
Article Revised on 05 March 2026,
Article Published on 16 March 2026

https://doi.org/10.5281/zenodo.19042946

***Corresponding Author**
Ms. Shradha Shriram Hambire
B. Pharm Student, Swami Vivekanand College of Pharmacy, Udgir, Latur, Maharashtra, India.

How to cite this Article: Ms. Shradha Shriram Hambire[1]*, Mr. Shivraj Surayawanshi[1], Dr. Ganesh S. Tolsarwad[3] (2026). A Review on Nano Technology in Drug Delivery System. World Journal of Pharmaceutical Research, 15(6), 25–46.

1. ABSTRACT

Nanotechnology has revolutionized pharmaceutical drug delivery by enabling precise manipulation of materials at the nanoscale (1-100 nm) to improve therapeutic outcomes. Conventional drug delivery systems often face challenges such as poor solubility, low bioavailability, rapid clearance, and non-specific distribution, which can lead to reduced efficacy and increased side effects. Nanotechnology addresses these limitations through advanced nanocarriers like liposomes, polymeric nanoparticles, dendrimers, micelles, and metallic nanoparticles. These carriers allow drugs to be encapsulated, protected from degradation, and delivered in a controlled and targeted manner to specific tissues or cells, such as tumors or the central nervous system. This targeted approach enhances pharmacokinetics, reduces systemic toxicity, and supports sustained drug release, minimizing dosing frequency.

Applications of nanotechnology in pharmaceuticals include cancer therapy, neurological disorder treatment, and chronic disease management, where crossing biological barriers like the blood-brain barrier is critical. Furthermore, stimuli-responsive nanocarriers that react to pH, temperature, or enzymatic changes are paving the way for personalized medicine. Despite its promise, nanotechnology faces challenges related to toxicity, biocompatibility, regulatory approval, and large-scale manufacturing. Continued research and development are

essential to overcome these hurdles and fully realize the potential of nanotechnology in creating safer, more effective, and patient-centric drug delivery systems.

KEYWORDS: Nanotechnology, Drug Delivery Systems, Nanocarriers, Liposomes, Polymeric Nanoparticles, Dendrimers, Micelles, Metallic Nanoparticles, Targeted Drug Delivery, Controlled Release, Bioavailability. Pharmacokinetics, Cancer Therapy, Blood-Brain Barrier, Stimuli-Responsive Nanocarriers, Personalized Medicine, Biocompatibility, Toxicity, Regulatory Challenges, Pharmaceutical Applications.

2. INTRODUCTION

Drug delivery systems have evolved from simple oral tablets to sophisticated controlled release mechanisms. However, conventional systems often fail to achieve optimal therapeutic outcomes due to poor solubility, rapid clearance, and systemic side effects. Nanotechnology addresses these limitations by enabling targeted delivery, controlled release, and improved bioavailability.

Nanotechnology has emerged as a groundbreaking innovation in pharmaceutical sciences, particularly in drug delivery systems. It involves the design and application of materials at the nanoscale (1-100 nm) to enhance the therapeutic performance of drugs. Conventional drug delivery methods often face challenges such as poor solubility, low bioavailability, rapid clearance, and non-specific distribution, which can lead to reduced efficacy and undesirable side effects. Nanotechnology addresses these limitations by introducing advanced nanocarriers that enable precise drug encapsulation, targeted delivery, and controlled release. Nanocarriers such as liposomes, polymeric nanoparticles, dendrimers, micelles, and metallic nanoparticles are engineered to improve drug stability and solubility while minimizing degradation during transit. These systems allow drugs to reach specific tissues or cells, such as tumors or the central nervous system, thereby reducing systemic toxicity and improving therapeutic outcomes. Furthermore, nanotechnology facilitates crossing biological barriers like the blood-brain barrier, which is critical for treating neurological disorders.

2.1 These nanocarriers offer several advantages

Targeted Delivery: Direct drugs to specific cells or tissues, reducing systemic toxicity.

Controlled Release: Enable sustained or stimuli-responsive drug release (pH, temperature, enzymes).

Enhanced Bioavailability: Improve solubility and stability of poorly soluble drugs.
Barrier Penetration: Cross biological barriers like the blood-brain barrier for neurological treatments.

An additional advantage lies in stimuli-responsive nanocarriers, which release drugs in response to environmental triggers such as pH, temperature, or enzymatic activity, paving the way for personalized medicine. Applications of nanotechnology in drug delivery include cancer therapy, chronic disease management, and targeted treatments for complex conditions. Applications include cancer therapy, neurological disorders, and chronic disease management, making nanotechnology a cornerstone for personalized medicine. Despite its immense potential, nanotechnology faces challenges related to toxicity, biocompatibility, regulatory approval, and large-scale manufacturing. Continuous research and development are essential to overcome these hurdles and ensure safe, effective, and sustainable clinical translation. Nanotechnology thus represents a promising frontier in pharmaceutical innovation, offering solutions that can transform modern healthcare.

2.2 Fundamentals of Nanotechnology

Definition

Nanotechnology is the science and engineering of materials and devices at the nanoscale (1-100 nanometers). At this scale, materials exhibit unique physical, chemical, and biological properties that differ significantly from their bulk counterparts.

➤ Key Principles

- **Size Effect:** Properties such as melting point, conductivity, and reactivity change at the nanoscale.
- **Surface Area:** Nanoparticles have a high surface area-to-volume ratio, enhancing interactions with biological systems.
- **Quantum Effects:** At very small sizes, quantum phenomena influence optical and electronic behavior.

➤ Properties Relevant to Pharmaceuticals

- Biocompatibility: Safe interaction with biological tissues.
- Controlled Release: Ability to release drugs over time or in response to stimuli (pH, temperature).

- Targeting Capability: Surface modification allows site-specific delivery (e.g., tumor targeting).

3. Importance of Nanotechnology in Drug Delivery

Here's a detailed explanation of the Importance of Nanotechnology in Drug Delivery.

Why Nanotechnology Matters in Drug Delivery

Nanotechnology has become a cornerstone in modern pharmaceutical research because it addresses the limitations of conventional drug delivery systems and enables precision medicine. Its importance can be understood through several key aspects.

1. Overcoming Limitations of Traditional Drug Delivery

Poor Solubility: Many drugs have low water solubility, reducing absorption. Nanocarriers improve solubility by encapsulating drugs in nanoscale systems.

Low Bioavailability: Nanoparticles enhance absorption and protect drugs from degradation in the gastrointestinal tract.

Systemic Toxicity: Conventional chemotherapy affects healthy cells; nanotechnology enables targeted delivery to diseased tissues, reducing side effects.

2. Targeted Drug Delivery

Nanocarriers can be functionalized with ligands (antibodies, peptides) to deliver drugs directly to specific cells or tissues.

Example: Liposomal doxorubicin (Doxil) targets cancer cells, minimizing damage to healthy tissue.

3. Controlled and Sustained Release

Nanotechnology allows controlled release of drugs over time or in response to stimuli (pH, temperature, enzymes).

This reduces dosing frequency and improves patient compliance.

4. Crossing Biological Barriers

Nanoparticles can cross the Blood-Brain Barrier (BBB), enabling treatment of neurological disorders like Alzheimer's and Parkinson's.

Lipid nanoparticles (LNPs) are used for mRNA delivery in vaccines and gene therapy.

5. Enabling Advanced Therapies

Gene Therapy: Nanocarriers deliver DNA/RNA safely into cells.

mRNA Vaccines: LNPs protect fragile mRNA and ensure efficient cellular uptake.

Personalized Medicine: Nanotechnology supports patient-specific formulations based on genetic profiles.

6. Improved Therapeutic Index

Higher drug concentration at the target site with minimal systemic exposure.

Reduced toxicity and improved efficacy compared to conventional formulations.

7. Market and Industry Impact

Nanomedicine is one of the fastest-growing segments in pharma, projected to reach $500+ billion by 2032.

Regulatory bodies (FDA, EMA) have established guidelines for nanomedicines, signaling their importance in future drug development.

4. Types of Nanocarriers

Common nanocarriers include liposomes, polymeric nanoparticles, dendrimers, and metallic nanoparticles.

1. Liposomes

Liposomes are spherical vesicles composed of one or more phospholipid bilayers surrounding an aqueous core. They can encapsulate hydrophilic drugs in the core and hydrophobic drugs within the bilayer, making them versatile carriers. Liposomes are biocompatible, biodegradable, and widely used in cancer therapy, antifungal treatments, and vaccines. Surface modification with ligands or polymers (PEGylation) enhances targeting and prolongs circulation time. Their ability to reduce toxicity and improve bioavailability makes them a preferred choice for advanced drug delivery. However, challenges include stability issues, high production costs, and complex regulatory requirements for clinical approval.



Fig. : 1

➢ **Structure**

Phospholipid Bilayer: Similar to biological membranes.

Aqueous Core: Holds water-soluble drugs.

Surface Functionalization: Can be modified with ligands, antibodies, or polymers (e.g., PEGylation) for targeted delivery.

➢ **Key Features**

Biodegradable and Non-toxic: Safe for clinical use.

Versatile Drug Loading: Suitable for small molecules, peptides, proteins, and nucleic acids.

Customizable Size and Charge: Enables control over circulation time and tissue penetration.

➢ **Advantages**

Targeted Delivery: Ligand-modified liposomes can deliver drugs to specific cells (e.g., cancer cells).

Controlled Release: Can be engineered for sustained or stimuli-responsive release.

Reduced Toxicity: Minimizes exposure to healthy tissues.

Enhanced Bioavailability: Improves solubility of poorly soluble drugs.

➢ **Applications**

Cancer Therapy: Liposomal formulations of doxorubicin and paclitaxel.

Vaccines: Used in mRNA COVID-19 vaccines.

Antifungal and Antiviral Drugs: Amphotericin B liposomal formulations.

2. Polymeric Nanoparticles

Polymeric nanoparticles are solid colloidal particles made from biodegradable polymers such as PLGA, chitosan, or PEG. They offer controlled and sustained drug release, improving therapeutic efficiency and patient compliance. These carriers can be engineered for targeted delivery by surface functionalization with ligands or antibodies. Their high stability and customizable size make them suitable for delivering anticancer drugs, peptides, and proteins. Polymeric nanoparticles also protect drugs from degradation and enhance bioavailability. Despite their advantages, challenges include potential toxicity of polymers and scalability issues in manufacturing. They are widely researched for chronic disease management and precision medicine applications.



Fig.: 2.

➢ **Structure**

Core: Contains the drug, either dispersed or encapsulated.

Polymer Matrix: Provides stability and controls drug release.

Surface Functionalization: Modified with ligands, antibodies, or PEG for targeted delivery and prolonged circulation.

➢ **Key Features**

Controlled Release: Drugs can be released slowly over time.

Targeting Ability: Surface modification allows site-specific delivery.

Protection: Shields drugs from degradation in biological environments.

Versatility: Suitable for small molecules, proteins, and nucleic acids.

➢ Advantages

High stability and customizable size.

Reduced dosing frequency due to sustained release.

Enhanced bioavailability for poorly soluble drugs.

Ability to cross biological barriers when functionalized.

➢ Applications

Cancer Therapy: Targeted delivery of chemotherapeutic agents.

Gene Therapy: Delivery of DNA/RNA molecules.

Vaccines: Controlled antigen release for better immune response.

3. Metallic Nanoparticles

Metallic nanoparticles, such as gold, silver, and iron oxide, are widely used in drug delivery and diagnostic applications due to their unique optical, magnetic, and thermal properties.

They can be functionalized with drugs, targeting ligands, and polymers for site-specific delivery. Gold nanoparticles are commonly used in photothermal therapy, while iron oxide nanoparticles serve as MRI contrast agents. These carriers enable combined therapeutic and imaging applications (theranostics). Metallic nanoparticles offer high stability and multifunctionality but raise concerns about toxicity and long-term biocompatibility. Their ability to provide targeted delivery and diagnostic capabilities makes them valuable in advanced medical treatments.



Fig.3

➢ **Structure**

Core: Made of metal or metal oxide.

Surface Functionalization: Coated with polymers, ligands, or antibodies for stability and targeted delivery.

Drug Attachment: Drugs can be adsorbed, conjugated, or encapsulated on the nanoparticle surface.

➢ **Key Features**

High Surface Area: Allows efficient drug loading.

Multifunctionality: Enables combined therapy and imaging (theranostics).

Stimuli-Responsive: Can release drugs under specific conditions (heat, magnetic field, light).

➢ **Advantages**

Excellent stability and tunable size.

Ability to cross biological barriers.

Useful for targeted therapy and diagnostic imaging.

Enables photothermal and magnetic hyperthermia treatments.

➢ **Applications**

Cancer Therapy: Gold nanoparticles for photothermal therapy.

Imaging: Iron oxide nanoparticles as MRI contrast agents.

Drug Delivery: Targeted delivery of anticancer and antimicrobial drugs.

Theranostics: Combining therapy and diagnostics in one platform.

➢ **Challenges**

Potential toxicity and long-term biocompatibility concerns.

Complex synthesis and high cost.

Regulatory hurdles for clinical approval.

4. Dendrimers

Dendrimers are highly branched, tree-like macromolecules with a well-defined structure and multiple functional groups on their surface. This architecture allows high drug- loading capacity and precise control over size and functionality. Dendrimers exhibit excellent solubility and can carry multiple therapeutic agents or imaging molecules simultaneously.

They are used in gene therapy, anticancer drug delivery, and diagnostic applications. Surface modification enables targeted delivery and reduces toxicity. However, their synthesis is complex and costly, and biocompatibility remains a concern. Dendrimers represent a promising platform for multifunctional drug delivery systems due to their versatility and ability to penetrate biological barriers.



Fig.4

➢ Structure

Core: Central atom or molecule from which branches originate.

Branches (Generations): Repeated layers of branching units that increase size and functionality.

Surface Groups: Functional groups that can be modified for drug attachment or targeting.

➢ Key Features

Monodispersity: Uniform size and shape.

High Drug-Loading Capacity: Multiple functional groups allow attachment of drugs, imaging agents, or targeting ligands.

Precise Architecture: Enables controlled interaction with biological systems.

➢ Advantages

Excellent solubility and biocompatibility.

Ability to carry multiple drugs or therapeutic agents simultaneously.

Facilitates targeted delivery and controlled release.

Can penetrate biological barriers effectively.

➢ Applications

Cancer Therapy: Targeted delivery of chemotherapeutic drugs.

Gene Therapy: Transport of DNA/RNA molecules.

Diagnostics: Imaging agents for disease detection.

Antimicrobial Delivery: Enhanced penetration into infected tissues.

➢ Challenges

Complex and costly synthesis.

Potential toxicity at higher generations.

Regulatory hurdles for clinical approval.

5. Micelles

Micelles are nanoscale aggregates formed by amphiphilic molecules that arrange themselves into a core-shell structure in aqueous environments. The hydrophobic core solubilizes poorly water-soluble drugs, while the hydrophilic shell ensures stability in biological fluids. Micelles are simple to prepare and ideal for delivering hydrophobic chemotherapy drugs and antibiotics. They improve drug solubility, bioavailability, and circulation time. Functionalization of micelles with targeting ligands enhances site-specific delivery. Despite their advantages, micelles may face stability issues under physiological conditions and require careful formulation. They are widely used in cancer therapy and other treatments involving poorly soluble drugs.



Fig.5

➢ **Structure**

Core: Hydrophobic region that encapsulates poorly water-soluble drugs.

Shell: Hydrophilic layer that provides stability and prevents aggregation.

Surface Modification: Can be functionalized with ligands for targeted delivery.

➢ **Key Features**

Ideal for solubilizing hydrophobic drugs.

Simple and cost-effective preparation.

Can be engineered for controlled drug release.

Biocompatible and biodegradable.

➢ **Advantages**

Improves drug solubility and bioavailability.

Enhances circulation time in the bloodstream.

Reduces systemic toxicity by targeting specific tissues.

Can be combined with polymers for better stability (polymeric micelles).

➢ **Applications**

Cancer Therapy: Delivery of hydrophobic chemotherapy drugs.

Antibiotics: Transport of poorly soluble antimicrobial agents.

Gene Delivery: Used in combination with other nanocarriers.

➢ **Challenges**

Stability issues under physiological conditions.

Limited drug-loading capacity compared to other nanocarriers.

Requires careful formulation to prevent premature drug release.

6. Carbon-Based Nanocarriers

Carbon-based nanocarriers include carbon nanotubes, graphene, and fullerenes, known for their high surface area, mechanical strength, and ability to penetrate cells. They are used for gene delivery, anticancer drug transport, and biosensing applications. Carbon nanotubes can carry drugs or genetic material and deliver them directly into cells, improving therapeutic efficiency. Functionalization of their surface enhances solubility and reduces toxicity. Despite their potential, concerns about biocompatibility and long-term safety remain significant challenges. Carbon-based nanocarriers represent a promising platform for advanced drug delivery and diagnostic systems, offering unique properties for targeted and personalized medicine.



Fig.6

➤ Structure

Carbon Nanotubes (CNTs): Cylindrical tubes of carbon atoms with single or multiple walls.

Graphene: A single layer of carbon atoms arranged in a hexagonal lattice.

Fullerenes: Hollow spherical molecules composed of carbon atoms.

Surface Functionalization: Modified with polymers, ligands, or biomolecules to improve solubility and biocompatibility.

➤ Key Features

High Drug Loading: Large surface area allows efficient drug adsorption or conjugation.

Cell Penetration: Ability to cross cell membranes for intracellular delivery.

Versatility: Can carry drugs, genes, or imaging agents.

Stimuli-Responsive: Functionalized carbon nanocarriers can release drugs under specific conditions.

➤ Advantages

Excellent mechanical and thermal stability.

Suitable for targeted and controlled drug delivery.

Potential for combined therapy and diagnostics (theranostics).

➢ Applications

Cancer Therapy: Delivery of chemotherapeutic drugs directly into tumor cells.

Gene Therapy: Transport of DNA/RNA molecules.

Biosensing and Imaging: Used in diagnostics and monitoring drug release.

➢ Challenges

Toxicity and Biocompatibility: Raw carbon nanostructures can be harmful; surface modification is essential.

Complex Manufacturing: Requires advanced techniques for uniformity.

Regulatory Approval: Safety concerns limit clinical translation.

5. Applications in Pharmaceutical Industry

Nanotechnology has transformed drug delivery by enabling precise targeting, controlled release, and improved bioavailability. Below are the major application areas:

1. Cancer Therapy

Problem: Conventional chemotherapy affects healthy cells, causing severe side effects.

Nanotech Solution

Liposomes (e.g., Doxil) deliver anticancer drugs directly to tumor cells using the Enhanced Permeability and Retention (EPR) effect.

Polymeric nanoparticles encapsulate drugs for sustained release.

Benefits

Reduced systemic toxicity

Higher drug concentration at tumor site

Example

Doxil (liposomal doxorubicin) approved by FDA for ovarian cancer and multiple myeloma.

2. Neurological Disorders

Challenge: Blood-Brain Barrier (BBB) prevents most drugs from reaching the brain.

Nanotech Solution

Ligand-functionalized nanoparticles (e.g., transferrin-coated) cross BBB.

Lipid nanoparticles (LNPs) used for mRNA delivery in neurodegenerative diseases.

Applications

Alzheimer's, Parkinson's, brain tumors.

3. Cardiovascular Diseases

Nanocarriers deliver anticoagulants or thrombolytic agents directly to clot sites.

Example

Nanoparticles carrying tissue plasminogen activator (IPA) for targeted thrombolysis.

4. Vaccine Delivery

Lipid Nanoparticles (LNPs) are the backbone of mRNA vaccines (e.g., COVID-19 vaccines).

Advantages

Protect fragile mRNA o Enable efficient cellular uptake.

Future

Personalized cancer vaccines using LNPs.

5. Gene Therapy

Nanocarriers deliver DNA/RNA safely into cells.

Example

siRNA-loaded nanoparticles for gene silencing in cancer therapy.

6. Oral Drug Delivery

Nanoemulsions and micelles improve solubility of poorly water-soluble drugs.

Impact

Enhanced absorption and bioavailability.

7. Targeted Delivery for Infectious Diseases

Nanoparticles carrying antibiotics or antivirals target infected tissues, reducing resistance and side effects.

8. Personalized Medicine

Nanotechnology enables patient-specific formulations based on genetic profiles.

Future Direction

Smart nanocarriers that release drugs in response to biomarkers.

Key Advantages Across Applications

Improved therapeutic index

Reduced dosing frequency

Lower toxicity

Enhanced patient compliance

6. Benefits of Nanotechnology

Benefits of Nanotechnology in Drug Delivery

1. Targeted Delivery

Nanocarriers can deliver drugs directly to diseased cells or tissues, reducing side effects and improving treatment precision.

2. Controlled and Sustained Release

Enables gradual or stimuli-responsive drug release (triggered by pH, temperature, or enzymes), enhancing therapeutic efficiency.

3. Improved Bioavailability

Enhances solubility and absorption of poorly water-soluble drugs, making them more effective.

4. Crossing Biological Barriers

Nanocarriers can penetrate barriers like the blood-brain barrier, enabling treatment of neurological disorders.

5. Reduced Toxicity

By minimizing exposure to healthy tissues, nanotechnology lowers systemic toxicity and adverse reactions.

6. Versatility

Suitable for a wide range of drugs small molecules, proteins, nucleic acids and supports personalized medicine.

7. Challenges

Detailed explanation of the challenges of nanotechnology in drug delivery systems:

1. Toxicity and Biocompatibility

Nanoparticles can interact with biological systems in unpredictable ways. Some materials may cause cytotoxicity, oxidative stress, or immune reactions, especially if not properly modified surface. Long-term safety data is still limited.

2. Stability and Shelf Life

Nanocarriers like liposomes and micelles can be unstable during storage, leading to aggregation, leakage of drugs, or degradation. Maintaining structural integrity under physiological conditions is a major challenge.

3. Manufacturing Complexity

Producing nanoparticles with uniform size, shape, and drug loading at an industrial scale is difficult. Advanced techniques are required for reproducibility, which increases cost and time.

4. Regulatory and Quality Control

Nanomedicines require specialized characterization methods (particle size, zeta potential, encapsulation efficiency). Regulatory frameworks are evolving, making approval processes lengthy and uncertain.

5. High Cost

Sophisticated equipment, raw materials, and stringent quality checks make nanotechnology-based formulations expensive, limiting accessibility and commercialization.

6. Biological Barriers

Although nanocarriers improve penetration, clearance by the reticuloendothelial system (RES) and unintended accumulation in organs like the liver and spleen remain concerns.

7. Environmental and Ethical Issues

Nanoparticle waste and its impact on ecosystems are poorly understood. Ethical concerns arise in clinical trials and patient safety.

8. Market Outlook

The global nanotechnology drug delivery market is projected to grow significantly, driven by advancements in personalized medicine. Brief market outlook for nanotechnology in drug delivery systems, based on the latest global reports and trends:

8.1 Global Market Size & Growth

The nanotechnology drug delivery market was valued at USD 82.5 billion in 2023 and is projected to reach USD 170.5 billion by 2032, growing at a CAGR of -8.4%. [dataintelo.com]

Other forecasts indicate the market could hit USD 178.3 billion by 2030 (CAGR-10.3%) and even USD 209.7 billion by 2034. [mordorinte...igence.com], [precedence...search.com]

Long-term projections suggest growth to USD 315.9 billion by 2035 (CAGR~11.3%). [transparen...search.com]

8.2 Key Growth Drivers

Rising prevalence of chronic diseases (cancer, cardiovascular, neurological disorders).

Demand for targeted and personalized medicine.

Technological advancements in nanocarriers (liposomes, polymeric nanoparticles, lipid nanoparticles).

Success of mRNA vaccines and RNA-based therapies, boosting LNP adoption.

Government initiatives and R&D investments in nanomedicine..

8.3 Market Segmentation

By Product Type: Nanoparticles, liposomes, micelles, dendrimers, nanotubes.

By Application: Oncology dominates, followed by cardiovascular, neurology, and infectious diseases.

By Region

North America leads due to strong R&D and regulatory support.

Asia-Pacific is the fastest-growing region, driven by public funding and manufacturing capacity.[mordorinte...igence.com]

8.4 Future Outlook

Personalized medicine and stimuli-responsive nanocarriers will drive innovation.

Integration with Al and big data for predictive nanocarrier design is emerging.[mdpi.com]

Manufacturing scalability and regulatory harmonization will be critical for commercialization.

9. Future Directions

Future directions of Nanotechnology in drug delivery system are as below

1. Personalized and Precision Medicine

Future nanocarriers will be designed to adapt to individual patient profiles. Stimuli-responsive systems (pH, temperature, enzyme-triggered) will allow drugs to release only in diseased environments, minimizing side effects and improving therapeutic outcomes.

2. Smart Nanocarriers

Development of "intelligent" nanocarriers capable of real-time sensing and controlled drug release is a major focus. These systems may integrate biosensors to monitor physiological conditions and adjust drug delivery dynamically.

3. Gene and RNA-Based Therapies

Nanotechnology will continue to advance nucleic acid delivery (siRNA, mRNA, CRISPR). Lipid nanoparticles (LNPs), proven in COVID-19 vaccines, will expand to treat genetic disorders, cancers, and rare diseases.

4. Theranostics (Therapy + Diagnostics)

Future nanocarriers will combine drug delivery with imaging capabilities, enabling simultaneous treatment and monitoring. Metallic nanoparticles and quantum dots will play a key role in cancer and neurological applications.

5. Nanobots and Active Targeting

Research is moving toward self-propelled nanobots that can navigate to specific tissues and release drugs on demand. This could revolutionize localized therapy for tumors and hard-to-reach areas.

6. Integration with AI and Big Data

Artificial intelligence will help design optimized nanocarriers by predicting drug-nanoparticle interactions and improving formulation efficiency, accelerating personalized treatment development.

7. Overcoming Regulatory and Manufacturing Challenges

Future efforts will focus on scalable production, standardized characterization, and global regulatory frameworks to ensure safety and affordability.

10. Case Studies

Detailed explanation of major case studies in nanotechnology-based drug delivery.

1. Doxil® (Pegylated Liposomal Doxorubicin)

- Overview: First FDA-approved nanomedicine (1995) for cancer treatment.
- Technology: Doxorubicin encapsulated in PEGylated liposomes to improve circulation time and reduce cardiotoxicity.
- Impact: Enhanced tumor targeting via the Enhanced Permeability and Retention (EPR) effect; significantly reduced side effects compared to conventional doxorubicin.
- Lesson: Demonstrated the clinical success of liposomal formulations in oncology.

2. AmBisome® (Liposomal Amphotericin B)

- Overview: Liposomal formulation of antifungal drug Amphotericin B.
- Technology: Liposomes reduce nephrotoxicity and improve drug distribution.
- Impact: Widely used for systemic fungal infections; improved patient safety and tolerability.
- Lesson: Nanotechnology can reformulate toxic drugs into safer alternatives.

3. Abraxane® (Albumin-Bound Paclitaxel)

- Overview: Nanoparticle albumin-bound paclitaxel for cancer therapy.
- Technology: Eliminates toxic solvents used in conventional paclitaxel formulations..
- Impact: Improved solubility, reduced hypersensitivity reactions, and better tumor penetration.
- Lesson: Protein-based nanoparticles can enhance delivery of hydrophobic drugs.

4. Onpattro® (Patisiran siRNA in Lipid Nanoparticles)

- Overview: First FDA-approved RNA interference (RNAi) therapy (2018). Technology: Lipid nanoparticles deliver siRNA to silence the TTR gene in hereditary amyloidosis.
- Impact: Opened the door for nucleic acid-based therapies using nanocarriers.
- Lesson: LNPs are critical for genetic and RNA-based treatments.

5. mRNA COVID-19 Vaccines (Pfizer-BioNTech & Moderna)

- Overview: Global breakthrough using lipid nanoparticles for mRNA delivery.
- Technology: LNPs protect fragile mRNA and enable efficient cellular uptake.
- Impact: Revolutionized vaccine technology and accelerated nanomedicine adoption..
- Lesson: Nanotechnology can scale rapidly for global health crises.

6. Ferumoxytol (Iron Oxide Nanoparticles)

- Overview: Initially approved for iron deficiency anemia; repurposed as an MRI contrast agent.
- Technology: Superparamagnetic iron oxide nanoparticles provide imaging and therapeutic benefits.
- Impact: Demonstrates theranostic potential combining therapy and diagnostics.
- Lesson: Nanoparticles can serve dual roles in treatment and imaging.

11. REFERENCES

1 Bhatia T, Singh P. Conventional versus nanotechnology for drug delivery system- a review.
2 Chitikela N, Chaitanya B. Current Advances in Nanotechnology-Based Drug Delivery Systems.
3 Hamidjavaid. Applications of nanotechnology in drug delivery systems.
4 Gurule SR, Bhabad PU, Pawar PR, Prajapati HR. Nanotechnology in drug delivery: A comprehensive review.
5 Allen TM, Cullis PR. Liposome Drug Delivery Systems: From Concept to Clinical Applications. Adv. Drug Deliv. Rev., 2013; 65(1): 36-48.
6 Kumar R, Singh B, Sharma S, Kumar S. Polymeric Nanoparticles for Drug Delivery. Int. J. Pharm., 2016; 512(1-2): 191-205.
7 Cheng Y, Xu Z, Ma M, Ye P, Su R. Dendrimers for Drug Delivery. Chem. Soc. Rev., 2011; 40(5): 2982 3007.
8 Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an Emerging Platform for Cancer Therapy. Nat. Nanotechnol., 2007; 2(12): 751-60.
9 Food and Drug Administration. Liposome Drug Products Chemistry, Manufacturing, and Controls: Guidance for Industry. Silver Spring (MD): U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2018.
10 European Medicines Agency. Onpattro (Patisiran) Lipid Nanoparticle siRNA Therapy. Amsterdam: European Medicines Agency: 2018.
11 Doxil®, Abraxane®, and mRNA COVID-19 vaccines [Clinical Reviews].
12 Grand View Research. Nanotechnology Drug Delivery Market Size, Share & Trends Analysis Report. San Francisco (CA): Grand View Research; 2023.

13 Fortune Business Insights. Nanomedicine Market Size, Share & COVID-19 Impact Analysis. Pune (MH): Fortune Business Insights; 2023.

14 Nanomedicine: Future Directions in Drug Discovery [Editorial]. Nat. Rev. Drug Discov., 2023; 22(1): 1.